A recent study demonstrated that PARP inhibitors induce pyroptosis in ovarian cancer via a TNF–caspase-8–GSDMD/E axis, generating immunogenic cell death that remodels the tumor immune microenvironment and expands T cells specific for tumor-derived neoantigens. Here, GSDMD is linked to ovarian carcinoma.